Mumbai: Pharmaceutical firm Aurobindo Pharma said it has received US regulatory approval to market Zaleplon capsules, used in the treatment of insomnia.
“The company has received final approval from the US Food and Drug Administration Approval (US FDA) to manufacture and market Zaleplon Capsules in variants of 5 mg and 10 mg,” Aurobindo said in a filing to the Bombay Stock Exchange.
Zaleplon capsules are generic equivalent of Kings Pharmaceuticals’ Sonata Capsules, it added.
Aurobindo Pharma has already launched the product in the US market, the company said, adding it is the 70th Abbreviated New Drug Application (ANDA) approval from the US regulator.
Shares of the company were trading at Rs 277, up 2.20% in the trade on the BSE.